Literature DB >> 7475260

Benign supraclavicular tumorous lymphangiectasia--a new disease?

S Preyer1, E Kaiserling, H Heinle, E Földi, H P Zenner, M Földi.   

Abstract

We describe an isolated recurrent non-inflammatory tumorous swelling of the supraclavicular fossa in four premenopausal women. Ultrasonography, magnetic resonance imaging and computer tomography of the neck each suggested an inhomogeneous mass consistent with "lymphangioma." In each patient the clinical course and histopathologic findings suggested that the swellings were due to chronic localized lymph stasis with subsequent lymphangiectasia, possibly initiated by intermittent obstruction of the juncture of the thoracic or right lymph duct with the internal jugular vein. Enlargement may have been hormonally triggered by estrogens as each woman was taking oral contraceptive pills at the onset of the disease. To characterize this unique entity, we have termed the disorder benign supraclavicular tumorous lymphangiectasia.

Entities:  

Mesh:

Year:  1995        PMID: 7475260

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  3 in total

1.  Spontaneous cervical swelling syndrome as a rare cause of neck edema: case series and literature review.

Authors:  Albrecht Betrains; Robert Hermans; Olivier Gheysens; Vincent Vander Poorten; Willy E Peetermans; Steven Vanderschueren
Journal:  Oxf Med Case Reports       Date:  2021-05-24

2.  [Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology].

Authors:  E Kaiserling
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

Review 3.  Recurrent thoracic duct cyst of the left supraclavicular fossa: A retrospective study of 6 observational case series and literature review.

Authors:  Julie Planchette; Clara Jaccard; Audrey Nigron; Jean-Baptiste Chadeyras; Guillaume Le Guenno; Benjamin Castagne; Yvan Jamilloux; Anne-Sophie Resseguier; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.